A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

Trial Profile

A Phase 2 Open Label Extension Study of Conatumumab and AMG 479

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Conatumumab (Primary) ; Ganitumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Cancer; Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Amgen; NantCell
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 25 Jan 2018.
    • 27 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 25 Jan 2018.
    • 14 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top